9 December 2004 Use of EPO as an adjuvant in PDT of brain tumors to reduce damage to normal brain
Author Affiliations +
Abstract
The potential for the use of photodynamic therapy (PDT) after resection of brain tumors is currently limited by the ensuing side effects. These include direct non-specific tissue damage due to the photodynamic action and elevated intracranial pressure as a result of edema and subsequent indirect tissue damage. Erythropoietin (EPO) has been recognized to confer resistance to apoptosis of neurons and endothelial cells in the brain. Here we present preliminary results of the combination of Photofrin – PDT and EPO in the treatment of rat brain astrocytomas in vivo and its ability to increase the therapeutic ratio versus stand alone PDT. The effects of the combination treatment are characterized in normal rat brain based on tissue damage (using TTC as a live cell stain) and monitoring intracranial pressure (ICP) for 24 hours following surgery, using a piezoelectric transducer. To access tumor cell kill, EGFP transduced astrocytoma cell line, CNS-1_gfp, is implanted in the cortex of Lewis rats through a craniotomy, allowed to grow to a diameter of 3mm. Immediately after PDT tumors are excised with the aid of a fluorescence microscope, desaggregated, counted under fluorescence and plated for colony forming assays. Tumor cell kill due to PDT is compared in the presence and absence of EPO.
© (2004) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Cesar A. Rendon, Cesar A. Rendon, Lothar Lilge, Lothar Lilge, } "Use of EPO as an adjuvant in PDT of brain tumors to reduce damage to normal brain", Proc. SPIE 5578, Photonics North 2004: Photonic Applications in Astronomy, Biomedicine, Imaging, Materials Processing, and Education, (9 December 2004); doi: 10.1117/12.567378; https://doi.org/10.1117/12.567378
PROCEEDINGS
7 PAGES


SHARE
Back to Top